WHO keen on meningitis vaccine as GSK makes EU filing
This article was originally published in Scrip
Executive Summary
The World Health Organization would very much like GlaxoSmithKline to enter its quadrivalent paediatric conjugated meningitis vaccine, Nimenrix in its prequalification vaccine programme, to fulfil an urgent health need. "We would welcome a GSK prequalification application because this vaccine is needed in developing countries," David Wood, head of the WHO prequalification vaccine programme told Scrip: "One of the priority vaccines that we would like to see prequalified in 2011-12 is a quadrivalent vaccine that is conjugated," he explained.